BCL2 and melanoma: In addition to restoring apoptosis, treatment of melanoma cells with ASO-4625 led to a 50–60% reduction in VEGF secretion and a 10–12 fold decrease in the vascularization of matrigel plugs subcutaneously injected into mice; reiterating Bcl-2’s relevance in angiogenesis and implicating Bcl-xL’s role in it [65].